Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition

Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of cancer, but the strategies employed have continued to evolve. Recently, much clinical focus has been on combining targeted therapies with ICI for the purpose of manipulating...

Descripción completa

Detalles Bibliográficos
Autores principales: Daly, Roger J., Scott, Andrew M., Klein, Oliver, Ernst, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523960/
https://www.ncbi.nlm.nih.gov/pubmed/36175961
http://dx.doi.org/10.1186/s12943-022-01656-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523960/
https://www.ncbi.nlm.nih.gov/pubmed/36175961
http://dx.doi.org/10.1186/s12943-022-01656-z

Ejemplares similares